Senores Pharmaceuticals LimitedQ1 FY27 Results & Financial Update
Senores Pharmaceuticals Limited: Q1 FY27 consolidated results and company financials – revenue ₹180.21 Cr, PAT ₹30.45 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Senores Pharmaceuticals price & chart
Market priceLoading…
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Senores Pharmaceuticals Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Profit before tax was ₹39.46 Cr for the reported quarter. EPS was ₹6.61 for the reported quarter.
Consolidated revenue from operations for Q1 FY27 reached INR 180 crores, up 36% year-on-year, driven by robust performance in regulated markets.
Consolidated EBITDA for Q1 FY27 surged 87% year-on-year to INR 54 crores, with EBITDA margins expanding by 810 basis points year-on-year to almost 30%. Profit after tax grew 56% year-on-year to INR 31 crores.
Management reaffirmed guidance for FY27 expecting revenue growth of 30% to 40% and PAT growth of 50% to 60%, with a long-term goal of achieving INR 2,500 crores to INR 3,000 crores in revenue over the next three to four years.
Profit after tax was ₹30.45 Cr for the reported quarter. EPS was ₹6.61 for the reported quarter.
01 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹180.21 Cr |
| Total income | ₹183.02 Cr |
| Profit before tax | ₹39.46 Cr |
| Profit after tax | ₹30.45 Cr |
| EPS | ₹6.61 |
02 · Why it moved
Why the quarter looked the way it did
What drove margins
Sequential moderation in absolute EBITDA and net profit was clarified by management to be driven primarily by zero foreign exchange fluctuation gains in Q1 FY27 compared to INR 14 crores to INR 15 crores in the previous quarter.
03 · Demand, customers & order book
Where demand is coming from
Every product in the pipeline or approved ANDA inventory is commercially mapped with a defined partner or strategy from day one, eliminating unallocated portfolio overhang.
04 · Segments, products & geography
Which parts of the business are doing the work
Geography and market mix
The Chhatral facility underwent a PIC/S inspection during the period, which will unlock access to mid-tier markets such as South Africa, Mexico, and Vietnam.
05 · Capacity, projects & execution
What is being built, commissioned or delivered
Capacity, production and utilisation
The Baroda-based USFDA-approved Apnar facility produced about 30 million units in Q1 FY27, operating at 80% to 90% capacity while undergoing work for a third and fourth production line.
Management proposed a change in the object of IPO proceeds, scaling down the sterile injectable project into a small pilot plant and reallocating funds to expand oral solid capacities in the US and India.
06 · Reported developments
What changed operationally
Regulated market business delivered strong performance with 42% year-on-year revenue growth, supported by portfolio expansion and differentiated sales channels.
Approved ANDAs nearly doubled over the past 12 months, expanding from 30 as of June 2025 to 58 as of June 2026, out of which 23 have been commercialized.
Emerging markets revenue grew by approximately 30% year-on-year with EBITDA margins improving toward the mid-teens, generating INR 18 crores of operating cash flow during the quarter.
07 · Pressure points & risks
What is not going smoothly
India branded generics segment registered a minor de-growth of 2% during Q1 FY27 as management intentionally shifted focus from top-line sales toward profitability after a 5x surge in the previous year.
08 · Cash flow & balance sheet
Profit is one thing. Cash and funding tell another part of the story.
Operating cash flow conversion improved significantly due to disciplined working capital management, improved operational efficiency, and tighter execution.
09 · Management guidance & targets
What management is targeting from here
US-specific sales, marketing, and distribution subsidiaries Zoraya and Amerisyn are scheduled to commence operations around September and October of the fiscal year.
Management expects revenue growth of approximately 30% to 40% and PAT growth of 50% to 60% for FY27, with similar growth trajectories thereafter.
The company targets reaching INR 2,500 crores to INR 3,000 crores in revenue in three to four years based on its current approved portfolio, pipeline filings, and CDMO verticals.
10 · Management call deep dive
What management said on the conference call
Operating takeaways
9 key pointsThe Chhatral facility underwent a PIC/S inspection during the period, which will unlock access to mid-tier markets such as South Africa, Mexico, and Vietnam.
US-specific sales, marketing, and distribution subsidiaries Zoraya and Amerisyn are scheduled to commence operations around September and October of the fiscal year.
Every product in the pipeline or approved ANDA inventory is commercially mapped with a defined partner or strategy from day one, eliminating unallocated portfolio overhang.
The Baroda-based USFDA-approved Apnar facility produced about 30 million units in Q1 FY27, operating at 80% to 90% capacity while undergoing work for a third and fourth production line.
Management proposed a change in the object of IPO proceeds, scaling down the sterile injectable project into a small pilot plant and reallocating funds to expand oral solid capacities in the US and India.
Sequential moderation in absolute EBITDA and net profit was clarified by management to be driven primarily by zero foreign exchange fluctuation gains in Q1 FY27 compared to INR 14 crores to INR 15 crores in the previous quarter.
Operating cash flow conversion improved significantly due to disciplined working capital management, improved operational efficiency, and tighter execution.
Management expects revenue growth of approximately 30% to 40% and PAT growth of 50% to 60% for FY27, with similar growth trajectories thereafter.
The company targets reaching INR 2,500 crores to INR 3,000 crores in revenue in three to four years based on its current approved portfolio, pipeline filings, and CDMO verticals.
Important analyst Q&A
2 key pointsManagement clarified that emerging market EBITDA margins typically peak in H2 due to seasonality, and reiterated full-year margin guidance of 18% to 20%.
Total capex for FY27 across subsidiaries is planned at INR 100 crores to INR 120 crores, primarily directed toward oral solid capacity expansion and the injectable pilot plant.
11 · Key Q&A
The quarter, answered directly
What is the clearest takeaway from Q1 FY27?
Profit before tax was ₹39.46 Cr for the reported quarter. EPS was ₹6.61 for the reported quarter.
What drove revenue or demand?
Every product in the pipeline or approved ANDA inventory is commercially mapped with a defined partner or strategy from day one, eliminating unallocated portfolio overhang.
What mattered most for margins or profitability?
Sequential moderation in absolute EBITDA and net profit was clarified by management to be driven primarily by zero foreign exchange fluctuation gains in Q1 FY27 compared to INR 14 crores to INR 15 crores in the previous quarter.
What changed operationally beyond the headline numbers?
The Baroda-based USFDA-approved Apnar facility produced about 30 million units in Q1 FY27, operating at 80% to 90% capacity while undergoing work for a third and fourth production line.
What is management guiding or targeting from here?
US-specific sales, marketing, and distribution subsidiaries Zoraya and Amerisyn are scheduled to commence operations around September and October of the fiscal year.
What are the main pressure points disclosed for the quarter?
India branded generics segment registered a minor de-growth of 2% during Q1 FY27 as management intentionally shifted focus from top-line sales toward profitability after a 5x surge in the previous year.
12 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.